Isomerization of a Single Aspartyl Residue of Anti-Epidermal Growth Factor Receptor Immunoglobulin γ2 Antibody Highlights the Role Avidity Plays in Antibody Activity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
A new isoform of the light chain of a fully human monoclonal immunoglobulin gamma2 (IgG2) antibody panitumumab against human epidermal growth factor receptor (EGFR) was generated by in vitro aging. The isoform was attributed to the isomerization of aspartate 92 located between phenylalanine 91 and histidine 93 residues in the antigen-binding region. The isomerization rate increased with increased temperature and decreased pH. A size-exclusion chromatography binding assay was used to show that one antibody molecule was able to bind two soluble extracellular EGFR molecules in solution, and isomerization of one or both Asp-92 residues deactivated one or both antigen-binding regions, respectively. In addition, isomerization of Asp-92 showed a decrease in in vitro potency as measured by a cell proliferation assay with a 32D cell line that expressed the full-length human EGFR. The data indicate that antibodies containing either one or two isomerized residues were not effective in inhibiting EGFR-mediated cell proliferation, and that two unmodified antigen binding regions were needed to achieve full efficacy. For comparison, the potency of an intact IgG1 antibody cetuximab against the same receptor was correlated with the bioactivity of its individual antigen-binding fragments. The intact IgG1 antibody with two antigen-binding fragments was also much more active in suppressing cell proliferation than the individual fragments, similar to the IgG2 results. These results indicated that avidity played a key role in the inhibition of cell proliferation by these antibodies against the human EGFR, suggesting that their mechanisms of action are similar.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, if a basic species arises due to isomerization or succinimide, there may be inactivation of the molecule or an illicit immune response. 32”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [32]
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Biophysical Chemistry: Part II: Techniques for the Study of Biological Structure and Function
Cantor, C. R., & SCHIMMEL, P. R. (1980) · Cited by 861
On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.
Parham, P. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.6.2895 · Cited by 413
Trafficking of the ErbB receptors and its influence on signaling
Wiley, H. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00002-8 · Cited by 348
CLARKE, S. (1987) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1987.tb03390.x · Cited by 338
Cleland, J. L., Lam, X., Kendrick, B., Yang, J., Yang, T., Overcashier, D., Brooks, D., Hsu, C., & Carpenter, J. F. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200103)90:3<310::aid-jps6>3.0.co;2-r · Cited by 299
Isoaspartate in peptides and proteins: formation, significance, and analysis
Aswad, D. W., Paranandi, M. V., & Schurter, B. T. (2000) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(99)00230-7 · Cited by 266
Dillon, T. M., Bondarenko, P. V., Rehder, D. S., Pipes, G. D., Kleemann, G. R., & Ricci, M. S. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.01.016 · Cited by 189
Self-citationGabrielson, J. P., Brader, M. L., Pekar, A. H., Mathis, K. B., Winter, G., Carpenter, J. F., & Randolph, T. W. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20760 · Cited by 175
Oliyai, C., & Borchardt, R. T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018981231468 · Cited by 148
Research works printed but not linked: 46
- Carpenter G., 2000, Bioassays 22, 697−707.
- Wu D. G., 1990, Proc. Natl. Acad. Sci. U.S.A. 87
- Burgess A. W., 2003, Mol. Cell 12, 541−552.
- Franklin M. C., 2004, Cancer Cell 5, 317−328.
- Dawson J. P., 2005, Mol. Cell. Biol. 25, 7734−7742.
- Hynes N. E., 2005, Nat. Rev. Cancer, 5
- Herbst R. S., 2002, Cancer 94, 1593−1611.
- Kawamoto T., 1983, Proc. Natl. Acad. Sci. U.S.A. 80
- Foon K. A., 2004, Int. J. Radiat. Oncol. Biol. Phys., 58
- Scott A. M., 2007, Proc. Natl. Acad. Sci. U.S.A. 104
- Adams G. P., 2006, Clin. Cancer Res. 12, 1599−1605.
- Gan H. K., 2007, J. Biol. Chem., 282
- Geiger T., 1987, J. Biol. Chem., 262
- Oliyai C., 1994, Pharm. Res. 11, 751−758.
- Johnson B. A., 1989, J. Biol. Chem., 264
- Potter S. M., 1993, III, and IV, Protein Sci. 2, 1648−1663.
- Lam X. M., 1997, J. Pharm. Sci., 86
- Stephenson R. C., 1989, J. Biol. Chem., 264
- Xiao G., 2007, Anal. Chem. 79, 2714−2721.
- Cacia J., 1996, Biochemistry 35
- Harris R. J., 2001, J. Chromatogr. B: Biomed. Sci. Appl. 752, 233−245.
- Wakankar A. A., 2007, J. Pept. Sci., 96
- Wakankar A. A., 2007, Biochemistry 46, 1534−1544.
- Di Donato A., 1993, J. Biol. Chem., 268
- Zhang W., 2002, Pharm. Res. 19, 1223−1231.
- Chelius D., 2005, Anal. Chem. 77, 6004−6011.
- Qian R. L., 1997, J. Chromatogr. A, 787
- Santora L. C., 2001, Anal. Biochem. 299, 119−129.
- Yang X. D., 1999, Cancer Res. 59, 1236−1243.
- Jakobovits A., 2007, Nat. Biotechnol. 25, 1134−1143.
- Goldstein N. I., 1995, Clin. Cancer Res. 1, 1311−1318.
- Li S., 2005, Cancer Cell 7, 301−311.
- Harding J., 2005, Drugs Today 41, 107−127.
- Zhang Z., 2004, Anal. Chem. 76, 3908−3922.
- Gadgil H. S., 2006, Anal. Biochem. 355, 165−174.
- Korman A. J., 1987, Proc. Natl. Acad. Sci. U.S.A. 84
- Ritz-Timme S., 2002, Ageing Res. Rev., 1, 59
- Chu G. C., 2007, J. Pharm. Res., 24
- Pierce J. H., 1988, Science 239, 628−631.
- Yang S., 2006, Cancer Res. 66, 6990−6997.
- Chen Y. R., 2006, Oncogene 25, 1205−1215.
- Fan Z., 1993, Cancer Res. 53, 4322−4328.
- Fan Z., 1994, J. Biol. Chem., 269
- Honegger A., 2001, J. Mol. Biol., 309
- Friedman L. M., 2005, Proc. Natl. Acad. Sci. U.S.A. 102
- Foltz, I. N., King, C. T., and Liang, M. (2007) Panitumumab induces internalization of the epidermal growth factor receptor [abstract B43 plus poster], 17th American Association for Cancer Research−National Cancer Institute−European Organization for the Research and Treatment of Cancer (AACR-NCI Disclosure EORTC) International Conference on Molecular Targets and Cancer Therapeutics; Nov 14−18, 2005, Philadelphia, PA; p 136.
Cited by
Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,098
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Mass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 316
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Metadata
- Authors
- Rehder, D. S., Chelius, D., McAuley, A., Dillon, T. M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D. N., Matsumura, M., & Bondarenko, P. V.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Rehder, Douglas S.
- Bondarenko, Pavel V.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-01-31
- Volume
- 47
- Issue
- 8
- Pages
- 2518-2530
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2018172073
- Cited by
- 110
- References
- 24
- Citations by year
- 2025: 1 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 12 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 10 · 2013: 7 · 2012: 4
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- anti-EGFR monoclonal antibody, panitumumab, cetuximab, antibody avidity, antigen-binding region, in vitro aging
- MeSH terms
- Panitumumab, Alkylation, Amino Acid Sequence, Antibodies, Monoclonal, Antibody Affinity, Antibody Formation, Aspartic Acid, Cells, Cultured, Chromatography, High Pressure Liquid, Humans, Immunoglobulin gamma-Chains, Immunoglobulin Light Chains, Isomerism, Models, Molecular, Molecular Sequence Data, Oxidation-Reduction, Protein Processing, Post-Translational, Structure-Activity Relationship, Transferases, Protein Isoforms, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Isomerization of a Single Aspartyl Residue of Anti-Epidermal Growth Factor Receptor Immunoglobulin γ2 Antibody Highlights the Role Avidity Plays in Antibody Activity. https://app.cochat.ai/papers/10.1021/bi7018223
- The paper
- Rehder, D. S., Chelius, D., McAuley, A., Dillon, T. M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D. N., Matsumura, M., & Bondarenko, P. V. (2008). Isomerization of a Single Aspartyl Residue of Anti-Epidermal Growth Factor Receptor Immunoglobulin γ2 Antibody Highlights the Role Avidity Plays in Antibody Activity. Biochemistry. https://doi.org/10.1021/bi7018223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.